Clinical Trial Update: Hydralazine Valproate for Ovarian Cancer [Phase 3]

View source ↗

Summary

This update concerns a Phase 3 clinical trial evaluating a hydralazine and valproic acid combination for ovarian cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Hydralazine (hydralazine)
• Valproate (valproate)

Snippet

Sponsor: National Institute of Cancerología | Conditions: Ovarian Cancer | Phase 3 | Status: UNKNOWN